Skip to main content
EDX Medical Group Plc logo

EDX Medical Group Plc — Investor Relations & Filings

Ticker · EDX ISIN · GB00BNDMJS47 LEI · 213800BZVJZTMCZ6DJ63 Aquis Stock Exchange Human health and social work activities
Filings indexed 116 across all filing types
Latest filing 2024-09-02 Regulatory Filings
Country GB United Kingdom
Listing Aquis Stock Exchange EDX

About EDX Medical Group Plc

https://edxmedical.com/

EDX Medical Group Plc develops and provides digital diagnostic products and services for healthcare professionals. Its solutions are designed for the rapid detection and characterization of major diseases, enabling personalized treatment and improved patient outcomes. The company's primary focus areas are oncology, cardiology, and infectious diseases. Key offerings in oncology include comprehensive tumour profiling using whole exome and transcriptome sequencing, liquid biopsy analysis, and functional ex vivo assays that predict tumour response to specific therapies. The company also develops highly sensitive tests for early detection of cancers such as prostate and testicular cancer. In infectious diseases, EDX Medical develops point-of-care multiplex tests for conditions like sepsis and pneumonia. The company's approach integrates advanced molecular biology, genomic sequencing, and digital technologies across its laboratory-based services and point-of-care devices.

Recent filings

Filing Released Lang Actions
Distribution agreement with Caris Life Sciences
Regulatory Filings Classification · 98% confidence The document is a regulatory announcement (RNS) issued by EDX Medical Group PLC regarding a new distribution agreement with Caris Life Sciences. It details a business partnership and strategic expansion, which does not fit into specific financial reporting categories like 10-K, IR, or ER. As it is a general corporate announcement distributed via a Regulatory Information Service (RNS) and does not fall into the other specialized categories, it is classified as a Regulatory Filing.
2024-09-02 English
New 5-FU/Capecitabine Safety & Treatment Test
Regulatory Filings Classification · 98% confidence The document is a press release issued via the Regulatory News Service (RNS) by EDX Medical Group PLC. It announces a new business development (an exclusive agreement for intellectual property to develop a new cancer diagnostic test). Since this is a corporate announcement regarding business operations and strategic partnerships that does not fit into specific categories like financial reports, dividends, or M&A, it falls under the general regulatory announcement category.
2024-08-23 English
Investor Evening
Regulatory Filings Classification · 98% confidence The document is a press release distributed via RNS (Reach) announcing an upcoming 'Investor Evening' event where the company's CEO will engage with private investors. It does not contain financial results, board changes, or regulatory filings, but rather serves as a general corporate announcement regarding an event. Since it does not fit into specific categories like 'Investor Presentation' (which would contain the actual slides/data) or 'Earnings Release', it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2024-07-12 English
Exclusive partnership for cancer assay
Regulatory Filings Classification · 98% confidence The document is a press release distributed via the Regulatory News Service (RNS) of the London Stock Exchange. It announces a new commercial partnership between EDX Medical Group PLC and Curesponse Ltd. Since this is a general corporate announcement regarding business operations and partnerships that does not fit into specific categories like M&A (which usually implies a takeover or merger of entities) or financial reporting, it is classified as a Regulatory Filing (RNS).
2024-06-26 English
New development in cancer testing strategy
Regulatory Filings Classification · 98% confidence The document is a regulatory announcement (RNS) from EDX Medical Group PLC regarding a new strategic development in their cancer testing strategy. It is a corporate news release detailing a product launch and business strategy update, which falls under the 'Regulatory Filings' category as it is a general corporate announcement that does not fit into more specific categories like earnings releases or financial reports.
2024-06-20 English
Admission to Apex segment of AQSE Growth Market
Regulatory Filings Classification · 98% confidence The document is a regulatory announcement (RNS) from EDX Medical Group PLC regarding its admission to the Apex segment of the Aquis Stock Exchange. It is a corporate news release detailing a change in market status and trading eligibility, which does not fit into specific categories like financial reports, board changes, or dividend notices. As it is a general regulatory announcement provided via the RNS service, it falls under the RNS category.
2024-04-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.